Michael Wolff Jensen resigns from the Vicore board of directors and is replaced by Jacob Gunterberg as chairman of the board up until the annual general meeting in May 2022
Gothenburg, March 23, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (ATRAGs), today announces that Michael Wolff Jensen has resigned from the board of directors.Michael Wolff Jensen, who has been the chairman of the board of directors of Vicore Pharma Holding AB (publ) since 2020, has today informed the board of directors of his resignation as chairman and member of the board of directors due to personal reasons. Michael will leave Vicore’s board of directors with immediate